These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 7984527)

  • 21. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism.
    Schwarz J; Tatsch K; Arnold G; Gasser T; Trenkwalder C; Kirsch CM; Oertel WH
    Neurology; 1992 Mar; 42(3 Pt 1):556-61. PubMed ID: 1549216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.
    Leslie WD; Abrams DN; Greenberg CR; Hobson D
    J Nucl Med; 1996 Oct; 37(10):1589-91. PubMed ID: 8862288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography.
    Im JH; Chung SJ; Kim JS; Lee MC
    J Neurol Sci; 2006 May; 244(1-2):103-9. PubMed ID: 16473371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.
    Wenning GK; Donnemiller E; Granata R; Riccabona G; Poewe W
    Mov Disord; 1998 May; 13(3):438-45. PubMed ID: 9613734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. D2 receptor imaging with iodine-123-iodobenzamide brain SPECT in infants with hypoxic-ischemic brain injury.
    Kapucu LO; Koç E; Gücüyener K; Zenciroğlu A; Atalay Y; Unlü M; van Royen E
    J Nucl Med; 1998 Oct; 39(10):1703-7. PubMed ID: 9776272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study.
    Pizzolato G; Cagnin A; Rossato A; Chierichetti F; Fabbri M; Dam M; Ferlin G; Battistin L
    Adv Neurol; 1996; 69():467-73. PubMed ID: 8615167
    [No Abstract]   [Full Text] [Related]  

  • 27. SPET investigations in extrapyramidal diseases using specific ligands.
    Staffen W; Hondl N; Trinka E; Zenzmaier R; Ladurner G
    Nucl Med Commun; 1997 Feb; 18(2):159-63. PubMed ID: 9076772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis.
    Seppi K; Scherfler C; Donnemiller E; Virgolini I; Schocke MF; Goebel G; Mair KJ; Boesch S; Brenneis C; Wenning GK; Poewe W
    Arch Neurol; 2006 Aug; 63(8):1154-60. PubMed ID: 16908744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical impact of cerebral dopamine-D2 receptor scintigraphy].
    Larisch R; Klimke A
    Nuklearmedizin; 1998; 37(7):245-50. PubMed ID: 9830615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 123I-IBZM SPECT: reconstruction methodology and results in parkinsonism and dystonia.
    Berding G; Gratz KF; Kolbe H; Meyer GJ; Dengler R; Knoop BO; Hundeshagen H
    Nuklearmedizin; 1994 Oct; 33(5):194-9. PubMed ID: 7997377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experience with 123I-Iodobenzamide in the differential diagnosis of Parkinson's disease and Parkinson-plus disease].
    Paniagua Correa C; García Alonso P; Balsa Bretón MA; Mariana Monguía A; Penín González FJ; Pey Illera C
    Rev Esp Med Nucl; 2010; 29(2):57-62. PubMed ID: 20133020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study.
    Filippi L; Manni C; Pierantozzi M; Brusa L; Danieli R; Stanzione P; Schillaci O
    Nucl Med Commun; 2006 Apr; 27(4):381-6. PubMed ID: 16531926
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.
    Schwarz J; Tatsch K; Gasser T; Arnold G; Pogarell O; Künig G; Oertel WH
    Mov Disord; 1998 Jan; 13(1):16-9. PubMed ID: 9452320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
    Brücke T; Podreka I; Angelberger P; Wenger S; Topitz A; Küfferle B; Müller C; Deecke L
    J Cereb Blood Flow Metab; 1991 Mar; 11(2):220-8. PubMed ID: 1671782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine D2 receptor brain imaging in the neonatal period using 123I-IBZM SPECT.
    Tranquart F; Saliba E; Zimmer L; Barantin L; Lanneau M; Guilloteau D; Baulieu JL
    J Nucl Med; 1999 Dec; 40(12):2126-7. PubMed ID: 10616897
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
    Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK
    Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Antonini A; Benti R; De Notaris R; Tesei S; Zecchinelli A; Sacilotto G; Meucci N; Canesi M; Mariani C; Pezzoli G; Gerundini P
    Neurol Sci; 2003 Oct; 24(3):149-50. PubMed ID: 14598060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease.
    Chalon S; Emond P; Bodard S; Vilar MP; Thiercelin C; Besnard JC; Guilloteau D
    Synapse; 1999 Feb; 31(2):134-9. PubMed ID: 10024010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
    Seibyl JP; Zea-Ponce Y; Brenner L; Baldwin RM; Krystal JH; Offord SJ; Mochoviak S; Charney DS; Hoffer PB; Innis RB
    J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.